Precision medicine will create new inequalities if access remains limited.
open
Global / Unspecified, Global
WS02030
Genomic and biomarker-driven therapies will transform oncology and rare disease care, but high costs and limited capacity risk concentrating benefits in wealthy populations. Fair pricing, global data-sharing, and low-cost diagnostics will be critical.